Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 1/20 | 0.44 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | PTGFR | P43088 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.39 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3178620 | 1.00 | CPT1A (0.44) | CPT1ACPT1BMAPTPLA2G1BATG4B | |
| SCHEMBL3168231 | 0.90 | GRM5 (0.44) | CPT1ACPT1BMAPTPLA2G1BATG4B | |
| SCHEMBL3168219 | 0.90 | GRM5 (0.44) | CPT1ACPT1BMAPTPLA2G1BATG4B | |
| SCHEMBL3158771 | 0.89 | MAPT (0.41) | MAPTHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL3158762 | 0.89 | MAPT (0.41) | MAPTHSP90AA1HSP90AB1MEN1KMT2A | |
| SCHEMBL29950591 | 0.84 | HSP90AA1 (0.43) | MAPTHSP90AA1HSP90AB1ADORA3ADORA2B | |
| SCHEMBL8121187 | 0.82 | KMT2A (0.47) | CPT1ACPT1BMAPTPLA2G1BATG4B | |
| SCHEMBL8121188 | 0.82 | KMT2A (0.47) | CPT1ACPT1BMAPTPLA2G1BATG4B | |
| SCHEMBL8953420 | 0.81 | CA1 (0.45) | MAPTLMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16816111 | 0.81 | CA1 (0.45) | MAPTLMNAMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645760-B2 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-7645760-B2 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-7645760-B2 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-20060173004-A1 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | NOVARTIS AG (CH) | 2006-08-03 | — | — | US | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| EP-1558594-A2 | 1-(4-BENZYL-PIPERAZIN-1-YL)-3-PHENYL-PROPENONE DERIVATIVES | Novartis AG (CH) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004037796-A2 | 1-(4-BENZYL-PIPERAZIN-1-YL)-3-PHENYL-PROPENONE DERIVATIVES | NOVARTIS AG (CH) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173004-A1 | 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | CCR1, CCR3, CCR4 | CPT1A 1530/4885CPT1B 1501/4885MAPT 2279/4885 |
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | CPT1A 2068/4885CPT1B 1539/4885MAPT 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.